Skip to main content

History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial.

Citation
Group, L. A. H. E. A. D. R., et al. “History Of Cardiovascular Disease, Intensive Lifestyle Intervention, And Cardiovascular Outcomes In The Look Ahead Trial.”. Obesity (Silver Spring, Md.), pp. 247-258.
Center University of Washington
Author Look AHEAD Research Group, Cora E Lewis, John P Bantle, Alain G Bertoni, George Blackburn, Frederick L Brancati, George A Bray, Lawrence J Cheskin, Jeffrey M Curtis, Caitlin Egan, Mary Evans, John P Foreyt, Siran Ghazarian, Bethany Barone Gibbs, Stephen P Glasser, Edward W Gregg, Helen P Hazuda, Louise Hesson, James O Hill, Edward S Horton, Van S Hubbard, John M Jakicic, Robert W Jeffery, Karen C Johnson, Steven E Kahn, Abbas E Kitabchi, Dalane Kitzman, William C Knowler, Edward Lipkin, Sara Michaels, Maria G Montez, David M Nathan, Ebenezer Nyenwe, Jennifer Patricio, Anne Peters, Xavier Pi-Sunyer, Henry Pownall, David M Reboussin, Donna H Ryan, Thomas A Wadden, Lynne E Wagenknecht, Holly Wyatt, Rena R Wing, Susan Z Yanovski
Abstract

OBJECTIVE: To examine the effects of an intensive lifestyle intervention (ILI) on cardiovascular disease (CVD), the Action for Health in Diabetes (Look AHEAD) trial randomized 5,145 participants with type 2 diabetes and overweight/obesity to a ILI or diabetes support and education. Although the primary outcome did not differ between the groups, there was suggestive evidence of heterogeneity for prespecified baseline CVD history subgroups (interaction P = 0.063). Event rates were higher in the ILI group among those with a CVD history (hazard ratio 1.13 [95% CI: 0.90-1.41]) and lower among those without CVD (hazard ratio 0.86 [95% CI: 0.72-1.02]).

METHODS: This study conducted post hoc analyses of the rates of the primary composite outcome and components, adjudicated cardiovascular death, nonfatal myocardial infarction (MI), stroke, and hospitalization for angina, as well as three secondary composite cardiovascular outcomes.

RESULTS: Interaction P values for the primary and two secondary composites were similar (0.060-0.064). Of components, the interaction was significant for nonfatal MI (P = 0.035). This interaction was not due to confounding by baseline variables, different intervention responses for weight loss and physical fitness, or hypoglycemic events. In those with a CVD history, statin use was high and similar by group. In those without a CVD history, low-density lipoprotein cholesterol levels were higher (P = 0.003) and statin use was lower (P ≤ 0.001) in the ILI group.

CONCLUSIONS: Intervention response heterogeneity was significant for nonfatal MI. Response heterogeneity may need consideration in a CVD-outcome trial design.

Year of Publication
2020
Journal
Obesity (Silver Spring, Md.)
Volume
28
Issue
2
Number of Pages
247-258
Date Published
02/2020
ISSN Number
1930-739X
DOI
10.1002/oby.22676
Alternate Journal
Obesity (Silver Spring)
PMID
31898874
PMCID
PMC6980987
Download citation